U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07910903) titled 'Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma' on Oct. 27.
Brief Summary: This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma (MM)
Intervention:
DRUG: CM336
Specified dose on specified days
DRUG: CM313
S...